Goldman Sachs
EFTRW

Goldman Sachs’s eFFECTOR Therapeutics, Inc. Warrant EFTRW Stock Holding History

Goldman Sachs’s Portfolio EFTRW Stock Details EFTRW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-630,539
Closed -$757 – 6195
2024
Q2 		$757 Hold
630,539
– – ﹤0.01% 5616
2024
Q1 		$85.2K Hold
630,539
– – ﹤0.01% 5266
2023
Q4 		$45.5K Hold
630,539
– – ﹤0.01% 5387
2023
Q3 		$47.9K Hold
630,539
– – ﹤0.01% 5281
2023
Q2 		$86.4K Hold
630,539
– – ﹤0.01% 5382
2023
Q1 		$47.3K Hold
630,539
– – ﹤0.01% 5564
2022
Q4 		$48.9K Hold
630,539
– – ﹤0.01% 5599
2022
Q3 		$128K Buy
630,539
+125,000
+25% +$19.5K ﹤0.01% 5621
2022
Q2 		$101K Hold
505,539
– – ﹤0.01% 5866
2022
Q1 		$175K Hold
505,539
– – ﹤0.01% 5933
2021
Q4 		$445K Sell
505,539
-2,245
-0.4% -$2.82K ﹤0.01% 5456
2021
Q3 		$812K Buy
+507,784
New +$616K ﹤0.01% 4905

Goldman Sachs's EFTRW Position: Q3 2024 in Review

Goldman Sachs sold out of eFFECTOR Therapeutics, Inc. Warrant (EFTRW) in Q3 2024, closing a stake of 630,539 shares — an estimated $757 sold.

Goldman Sachs first reported a position in EFTRW in Q3 2021 and held it in 12 quarters. The position peaked at $812K in Q3 2021. 1 fund tracked by Wall St. Rank holds EFTRW as of Q3 2024.

  • Goldman Sachs reported no remaining eFFECTOR Therapeutics, Inc. Warrant position as of Q3 2024 after selling out during the quarter.
  • Goldman Sachs sold 630,539 eFFECTOR Therapeutics, Inc. Warrant shares in Q3 2024, an estimated $757.
  • Goldman Sachs first reported a position in eFFECTOR Therapeutics, Inc. Warrant in Q3 2021 and held it in 12 quarters.
  • Goldman Sachs's eFFECTOR Therapeutics, Inc. Warrant position peaked at $812K in Q3 2021.
  • 1 fund tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Warrant as of Q3 2024.

Based on Goldman Sachs's 13F filing for Q3 2024, filed 14 Nov 2024.